This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Warm Up Your Portfolio With These ETFs This Winter
by Sanghamitra Saha
Uncertainties are playing a big role in the Wall Street due to record-high inflation, Fed policy tightening and Omicron strain of coronavirus. Still, some ETFs may warm up your winter portfolio.
Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Will Pfizer ETFs Gain on Positive COVID-19 Booster Dose Data?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in the coronavirus vaccine.
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
IBM Posts Biggest Sales Growth in 11 Quarters: ETFs to Tap
by Sweta Killa
IBM reported its biggest quarterly sales growth in 11 quarters boosted by its bets in the high-margin cloud computing business.
5 Dividend ETFs Hovering at Record High
by Sanghamitra Saha
These dividend ETFs are hovering at a record high. Most of these ETFs offer yields higher than the benchmark U.S.-treasury yield and some possess stocks that have a strong history of hiking dividends regularly.
ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
ETFs in Focus Post Mixed IBM Q4 Earnings
by Sweta Killa
International Business Machines (IBM) reported robust fourth-quarter 2020 results wherein it beat earnings estimates but missed on revenues.
ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.